What drugs target P2Y12 receptor?

45+ drugs target P2Y12 receptor, including Group P+P, Clopidogrel, Prasugrel, Ticagrelor, Chewing Ticagrelor LD, Blinded clopidogrel, Patent clopidogrel.

P2Y12 receptor — Drug Target

45 drugs 29 marketed 13 in Phase 3

All drugs that target P2Y12 receptor — marketed and clinical-stage. Includes 13 drug classes acting on this target.

Drug classes

P2Y12 inhibitor · P2Y12 receptor antagonist / Antiplatelet agent · P2Y12 receptor antagonist (antiplatelet agent) · Antiplatelet agents · P2Y12 receptor antagonist / Thienopyridine antiplatelet agent · P2Y12 platelet receptor antagonist · P2Y12 receptor antagonist (thienopyridine) · P2Y12 receptor antagonist · P2Y12 receptor antagonist; antiplatelet agent · P2Y12 inhibitor (antiplatelet agent) · antiplatelet · Dual P2Y12 receptor antagonist / Antiplatelet agent

Marketed (29)

Group P+P · Huazhong University of Science and Technology · P2Y12 inhibitor · Cardiovascular
This drug works by inhibiting the P2Y12 receptor, preventing platelet activation and aggregation.
Clopidogrel, Prasugrel, Ticagrelor · Centre hospitalier de l'Université de Montréal (CHUM) · P2Y12 receptor antagonist / Antiplatelet agent · Cardiovascular
These are P2Y12 platelet adenosine diphosphate receptor antagonists that inhibit platelet aggregation and reduce thrombotic events.
Chewing Ticagrelor LD · Sheba Medical Center · P2Y12 receptor antagonist (antiplatelet agent) · Cardiovascular
Ticagrelor is a P2Y12 platelet receptor antagonist that inhibits platelet aggregation and reduces thrombotic events.
Blinded clopidogrel · VA Office of Research and Development · Antiplatelet agents · Metabolic
Patent clopidogrel · Hospital Central San Luis Potosi, Mexico · P2Y12 receptor antagonist / Thienopyridine antiplatelet agent · Cardiovascular
Clopidogrel inhibits platelet aggregation by blocking the P2Y12 adenosine diphosphate receptor on platelets.
Integral ticagrelor · Collegium Medicum w Bydgoszczy · P2Y12 platelet receptor antagonist · Cardiovascular
Ticagrelor is a P2Y12 platelet receptor antagonist that inhibits platelet aggregation and reduces thrombotic events.
Prasugrel Oral Tablet · Elliot Israel, MD · P2Y12 receptor antagonist (thienopyridine) · Cardiovascular
Prasugrel is a thienopyridine antiplatelet agent that irreversibly inhibits the P2Y12 adenosine diphosphate receptor on platelets, preventing platelet aggregation and thrombosis.
prasugrel or ticagrelor · University of Florida · P2Y12 receptor antagonist · Cardiovascular
Both prasugrel and ticagrelor are P2Y12 platelet adenosine diphosphate receptor antagonists that inhibit platelet aggregation and reduce thrombotic events.
clopidogrel (SR25990C) · Sanofi · P2Y12 receptor antagonist (thienopyridine) · Cardiovascular
Clopidogrel is a thienopyridine antiplatelet agent that irreversibly inhibits ADP-induced platelet aggregation by blocking the P2Y12 adenosine diphosphate receptor on platelets.
Clopidogrel reloading · University of Pecs · P2Y12 receptor antagonist / Thienopyridine antiplatelet agent · Cardiovascular
Clopidogrel reloading involves administering a higher initial dose of clopidogrel to rapidly achieve platelet inhibition in acute coronary syndromes or percutaneous coronary intervention.
Switch ticagrelor to clopidogrel · The First Affiliated Hospital with Nanjing Medical University · P2Y12 receptor antagonist; antiplatelet agent · Cardiovascular
Clopidogrel is a P2Y12 platelet adenosine diphosphate receptor antagonist that irreversibly inhibits platelet aggregation.
prasugrel / clopidogrel · Assistance Publique - Hôpitaux de Paris · P2Y12 receptor antagonist (thienopyridine) · Cardiovascular
Prasugrel and clopidogrel are both P2Y12 platelet adenosine diphosphate receptor antagonists that inhibit platelet aggregation and reduce thrombotic events.
Ticagrelor maintenance dose · Icahn School of Medicine at Mount Sinai · P2Y12 platelet receptor antagonist · Cardiovascular
Ticagrelor is a P2Y12 platelet receptor antagonist that irreversibly blocks ADP-induced platelet aggregation to prevent thrombotic events.
P2Y12 Receptor Antagonist · Fu Wai Hospital, Beijing, China · P2Y12 receptor antagonist · Cardiovascular
Blocks the P2Y12 adenosine diphosphate receptor on platelets to inhibit platelet aggregation and reduce thrombotic events.
CYP2C19 genotype guided P2Y12 monotherapy · St. Antonius Hospital · P2Y12 inhibitor (antiplatelet agent) · Cardiovascular
CYP2C19 genotype-guided P2Y12 monotherapy uses genetic testing to select appropriate P2Y12 inhibitor dosing or choice based on individual cytochrome P450 2C19 metabolizer status, optimizing antiplatelet efficacy while reducing bleeding risk.
Thienopyridine (open-label) · VA Office of Research and Development · P2Y12 receptor antagonist / Antiplatelet agent · Cardiovascular
Thienopyridines inhibit platelet aggregation by blocking the P2Y12 adenosine diphosphate receptor on platelets.
Clopidogrel only · Seung-Jung Park · P2Y12 receptor antagonist / Thienopyridine antiplatelet agent · Cardiovascular
Clopidogrel irreversibly inhibits platelet aggregation by blocking the P2Y12 adenosine diphosphate receptor, preventing blood clots.
Clopidogrel active metabolite · University of Florida · P2Y12 receptor antagonist / Antiplatelet agent · Cardiovascular
Clopidogrel active metabolite irreversibly inhibits platelet P2Y12 adenosine diphosphate receptors, preventing platelet aggregation and thrombus formation.
Prasugrel based standard DAPT · Research Maatschap Cardiologen Rotterdam Zuid · P2Y12 receptor antagonist (thienopyridine) · Cardiovascular
Prasugrel is a P2Y12 platelet receptor antagonist that irreversibly inhibits platelet aggregation as part of dual antiplatelet therapy (DAPT).
Ticagrelor 60 · Sheffield Teaching Hospitals NHS Foundation Trust · P2Y12 receptor antagonist (antiplatelet agent) · Cardiovascular
Ticagrelor 60 mg is a P2Y12 platelet receptor antagonist that inhibits platelet aggregation and reduces thrombotic events.
Group P+T · Huazhong University of Science and Technology · P2Y12 inhibitor · Cardiovascular
This drug works by inhibiting the P2Y12 receptor, preventing platelet activation and aggregation.
Clopirin 2 · Jeil Pharmaceutical Co., Ltd. · P2Y12 receptor antagonist / Antiplatelet agent · Cardiovascular
Clopirin 2 is an antiplatelet agent that inhibits platelet aggregation to reduce thrombotic events.
Ticagrelor or Prasugrel · St. Antonius Hospital · P2Y12 receptor antagonist · Cardiovascular
Both ticagrelor and prasugrel are P2Y12 receptor antagonists that inhibit platelet aggregation by blocking ADP-mediated platelet activation.
Prasugrel loading · Azienda Policlinico Umberto I · P2Y12 receptor antagonist (thienopyridine) · Cardiovascular
Prasugrel is a thienopyridine antiplatelet agent that irreversibly inhibits the P2Y12 adenosine diphosphate receptor on platelets, preventing platelet aggregation.
Clopidogrel loading · Azienda Policlinico Umberto I · P2Y12 receptor antagonist / Thienopyridine antiplatelet agent · Cardiovascular
Clopidogrel is a prodrug that irreversibly inhibits platelet aggregation by blocking the P2Y12 adenosine diphosphate receptor.
Clopidogrel 75 · US Department of Veterans Affairs · P2Y12 receptor antagonist / Thienopyridine antiplatelet agent · Cardiovascular
Clopidogrel irreversibly inhibits platelet aggregation by blocking the P2Y12 adenosine diphosphate receptor, preventing blood clots.
Clopidogrel treatment · VA Office of Research and Development · P2Y12 receptor antagonist / Thienopyridine antiplatelet agent · Cardiovascular
Clopidogrel inhibits platelet aggregation by blocking the P2Y12 adenosine diphosphate receptor on platelets.
Ticagrelor loading dose · Icahn School of Medicine at Mount Sinai · P2Y12 platelet receptor antagonist · Cardiovascular
Ticagrelor is a P2Y12 platelet receptor antagonist that irreversibly blocks ADP-induced platelet aggregation to prevent thrombotic events.
Ticagrelor- Delayed Administration · Massachusetts General Hospital · P2Y12 platelet receptor antagonist · Cardiovascular
Ticagrelor is a P2Y12 platelet receptor antagonist that inhibits platelet aggregation to prevent thrombotic events.

Phase 3 pipeline (13)

clopidogrel by chewing · Sheba Medical Center · antiplatelet · Cardiovascular
Clopidogrel inhibits platelet activation and aggregation by irreversibly inhibiting the P2Y12 receptor.
Clopidogrel (SR25990) · Sanofi · P2Y12 receptor antagonist / Thienopyridine antiplatelet agent · Cardiovascular
Clopidogrel is a thienopyridine antiplatelet agent that irreversibly inhibits ADP-induced platelet aggregation by blocking the P2Y12 adenosine diphosphate receptor on platelets.
Ticagrelor orodispersible tablets · Azienda Ospedaliero Universitaria di Sassari · P2Y12 receptor antagonist (antiplatelet agent) · Cardiovascular
Ticagrelor is a P2Y12 platelet receptor antagonist that reversibly inhibits ADP-induced platelet aggregation to prevent thrombotic events.
Clopidogrel and Ticagrelor · University of Patras · Dual P2Y12 receptor antagonist / Antiplatelet agent · Cardiovascular
This is a dual antiplatelet therapy combining two P2Y12 receptor antagonists that inhibit platelet aggregation through different binding mechanisms to reduce thrombotic events.
Standard antiplatelet · Beijing Tiantan Hospital · antiplatelet · Cardiovascular
Standard antiplatelet drugs work by inhibiting platelet activation and aggregation, preventing blood clots from forming.
Ticlopidine + Ginko biloba · Samsung Medical Center · antiplatelet · Cardiovascular
Ticlopidine inhibits platelet aggregation by irreversibly blocking ADP receptors on platelets, while Ginkgo biloba has antioxidant and anti-inflammatory properties.
conventional-dose ticagrelor · First Affiliated Hospital of Harbin Medical University · P2Y12 receptor antagonist · Cardiovascular
Ticagrelor is a platelet aggregation inhibitor that works by blocking the P2Y12 receptor.
Clopidogrel (Iscover/Plavix) · Stiftung Institut fuer Herzinfarktforschung · P2Y12 receptor antagonist / Thienopyridine antiplatelet agent · Cardiovascular
Clopidogrel irreversibly inhibits platelet aggregation by blocking the P2Y12 adenosine diphosphate receptor on platelets.
P2Y12 inhibitor de-escalation · Azienda Ospedaliera Universitaria Policlinico "G. Martino" · P2Y12 inhibitor · Cardiovascular
P2Y12 inhibitors block the action of ADP on the P2Y12 receptor, preventing platelet activation and aggregation.
clopidogrel plus aspirin · Catholic University of the Sacred Heart · antiplatelet · Cardiovascular
Clopidogrel is an antiplatelet medication that inhibits platelet activation and aggregation by irreversibly binding to the P2Y12 receptor, while aspirin is an antiplatelet medication that inhibits platelet aggregation by irreversibly acetylating the cyclooxygenase-1 enzyme.
Standard dose PTCY · Shanghai Jiao Tong University School of Medicine · P2Y12 inhibitor · Cardiovascular
PTCY is a small molecule that targets the P2Y12 receptor.
The Clopidogrel · Sichuan Provincial People's Hospital · antiplatelet · Cardiovascular
Clopidogrel inhibits platelet activation and aggregation by irreversibly inhibiting the P2Y12 receptor.
Ticagrelor standard tablets · Azienda Ospedaliero Universitaria di Sassari · P2Y12 receptor antagonist (antiplatelet agent) · Cardiovascular
Ticagrelor is a P2Y12 platelet receptor antagonist that reversibly inhibits ADP-induced platelet aggregation to prevent thrombotic events.

Phase 2 pipeline (2)

DAPT, Statin · Samsung Medical Center · Antiplatelet · Cardiovascular
DAPT inhibits platelet aggregation by blocking the P2Y12 receptor.
Discontinue Clopidogrel · Icahn School of Medicine at Mount Sinai · antiplatelet · Cardiovascular
Clopidogrel is a prodrug that is metabolized to its active form by CYP450 enzymes, primarily CYP2C19, which irreversibly inhibits platelet aggregation by blocking the P2Y12 receptor on platelets.

Phase 1 pipeline (1)

Antiplatelet or Anticoagulant Therapy · Syntrillo, Inc · Antiplatelet · Cardiovascular
Inhibits platelet aggregation